Latest news with #KrsnaaDiagnostics
Business Standard
13-05-2025
- Business
- Business Standard
Krsnaa Diagnostics consolidated net profit rises 10.41% in the March 2025 quarter
Sales rise 11.91% to Rs 186.08 crore Net profit of Krsnaa Diagnostics rose 10.41% to Rs 20.68 crore in the quarter ended March 2025 as against Rs 18.73 crore during the previous quarter ended March 2024. Sales rose 11.91% to Rs 186.08 crore in the quarter ended March 2025 as against Rs 166.28 crore during the previous quarter ended March 2024. For the full year,net profit rose 36.54% to Rs 77.61 crore in the year ended March 2025 as against Rs 56.84 crore during the previous year ended March 2024. Sales rose 15.74% to Rs 717.16 crore in the year ended March 2025 as against Rs 619.63 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 186.08166.28 12 717.16619.63 16 OPM % 28.4726.28 - 26.5123.28 - PBDT 50.5640.72 24 191.01144.55 32 PBT 28.6122.61 27 102.6970.01 47 NP 20.6818.73 10 77.6156.84 37
Time of India
24-04-2025
- Health
- Time of India
BMC's subsidised diagnostic tests scheme all set to restart
Mumbai: After a gap of four months, the civic administration could soon restart its ambitious Aapli Chikitsa programme to provide diagnostic tests for free or at subsidised rates to citizens. Lifenity Health Ltd , headquartered in Pune and with a laboratory in Lower Parel, has emerged as the lowest bidder in the BMC's tender process, offering a rate of Rs 90 against the estimated cost of Rs 100 for basic tests. The BMC subsidises these tests—nearly 100 basic tests and 40 advanced tests—by paying the difference to the empanelled company. The previously empanelled company, Krsnaa Diagnostics, had a rate of Rs 86 for basic tests. However, their nearly two-year tenure was marred by delays in handing over patients' diagnostic reports, disrupted service in many hospitals, as well as protests over BMC's alleged delays in clearing dues. This time around, a senior BMC official said, the rates were better discussed. "Against an estimated cost of Rs 376, we got a bid for Rs 495 for the advanced tests," he said. The official mentioned that the appointment of a contractor would be finalised soon as there is an "urgent requirement" to get the diagnostic process operational again in the city ahead of the monsoons. Over 4,000 blood samples would be collected every day on average by the Aapli Chikitsa contractor from the Brihanmumbai Municipal Corporation's public healthcare machinery—ranging from dispensaries, HBT or mohalla clinics, to suburban hospitals. Infectious diseases such as malaria, leptospirosis, gastroenteritis, hepatitis, and dengue are among the most commonly conducted tests in monsoons. This time around, the BMC received two bids for the tender—one from Lifinity and another from Thyrocare Lab. Samajwadi Party MLA and former BMC corporator Rais Shaikh said that the Aapli Chikitsa scheme is much needed and the municipal corporation should have ensured that a new contractor was appointed long before the earlier contract expired. "When the authorities knew that the contract was ending, they should have ensured that there is a new contractor in place. This gap with free diagnostic service only impacts citizens," Shaikh said. However, officials of the BMC denied that patients were affected by the delay in restarting the subsidised tests scheme. The old contract ended on December 15, 2024, but the BMC rolled out a standard operating procedure to get the tests done in-house. "The BMC invited bids and received bids from two diagnostic companies but could not finalise a company and award the contract as the companies failed to negotiate a lower price with the BMC," said an official. In the previous tender, Krsnaa Diagnostics was awarded the contract by the BMC for four years. But the total quantity of tests was fixed, and this amount got exhausted, effectively ending the contract. A public health expert said that the rates mentioned in the BMC's tender documents are not feasible to conduct basic tests. "Even if the costs of testing are low, how does one account for salaries of phlebotomists and paramedical workers at such low rates? Delays and protests are likely to continue," said the doctor, who didn't want to be identified.
Time of India
23-04-2025
- Business
- Time of India
Top stocks to buy today: Stock recommendations for April 23, 2025
Top stocks to buy (AI image) Stock market recommendations : According to Mehul Kothari, DVP - Technical Research, Anand Rathi Shares and Stock Brokers, SJVN, IDBI Bank and Krsnaa Diagnostics are the top stocks to buy today: SJVN: BUY in ₹100–₹96 Range | Stop Loss: ₹89 | Target: ₹118 SJVN has shown a strong breakout today with significant volume support, confirming a higher top and higher bottom structure on the daily chart. The stock has also surpassed its March high, indicating renewed bullish momentum. On the weekly timeframe, a double bottom-like formation is visible, strengthening the reversal case. Momentum oscillators have given breakout signals, aligning with the price action. Traders are advised to buy SJVN in the ₹100–₹96 range, keeping a stop-loss at ₹89 and targeting ₹118 in the near term. IDBI BANK LTD: BUY in ₹86–₹84 Range | Stop Loss: ₹79 | Target: ₹95 IDBI Bank has witnessed a major range breakout today, notably closing above its 200-day SMA for the first time since October 2024. This breakout, accompanied by rising volumes and strength in ADX (now above 20), suggests the beginning of a trending phase. The technical setup points towards sustained momentum, offering a good buying opportunity. Traders are advised to buy IDBI in the ₹86–₹84 range, with a stop-loss at ₹79 and a target of ₹95. KRSNAA DIAGNOSTIC: BUY in ₹800–₹790 Range | Stop Loss: ₹755 | Target: ₹890 Krsnaa Diagnostics is currently consolidating, forming a potential inverse head and shoulder pattern near its 200 DEMA. The diagnostics sector is showing renewed traction, and this stock is on the verge of a breakout above the ₹820 level. A breakout here could trigger strong upside momentum supported by sectoral strength and technical pattern confirmation. Traders are advised to buy Krsnaa Diagnostic in the ₹800–₹790 range, with a stop-loss at ₹755, aiming for a target of ₹890. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
